Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16276485 | 0.87 | MAPK14 (0.41) | MAPK14BCHEACHETRPV1SRC | |
| SCHEMBL16132335 | 0.82 | TDO2 (0.43) | BCHEACHETRPV1SCN5ASCN9A | |
| SCHEMBL16132341 | 0.80 | ALDH1A1 (0.46) | TRPV1CYP2A6 | |
| SCHEMBL10066076 | 0.79 | CYP2A6 (0.59) | MAPK14BCHEACHETRPV1NPY5R | |
| SCHEMBL1370255 | 0.78 | MAPK14 (0.53) | MAPK14BCHEACHETGFBR1TGFBR2 | |
| SCHEMBL1741840 | 0.78 | ALDH1A1 (0.44) | TRPV1ABL1GAACYP2A6 | |
| SCHEMBL25491392 | 0.78 | MAPK14 (0.41) | MAPK14SRCABL1NPY5RGRM5 | |
| SCHEMBL30458217 | 0.76 | MAPK14 (0.45) | MAPK14BCHEACHENPY5RTGFBR1 | |
| SCHEMBL16132299 | 0.76 | CYP2A6 (0.61) | NPY5RCYP2A6 | |
| SCHEMBL15638862 | 0.76 | RORB (0.46) | MAPK14BCHEACHESCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | MAPK14 1466/4885BCHE 3826/4885ACHE 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.